GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » ROCE %

CLCS (Cell Source) ROCE % : 0.00% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cell Source ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cell Source's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Cell Source ROCE % Historical Data

The historical data trend for Cell Source's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source ROCE % Chart

Cell Source Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cell Source Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cell Source ROCE % Calculation

Cell Source's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-4.273/( ( (0.41 - 13.044) + (0.195 - 15.807) )/ 2 )
=-4.273/( (-12.634+-15.612)/ 2 )
=-4.273/-14.123
=30.26 %

Cell Source's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-3.648/( ( (0.43 - 17.749) + (0.265 - 19.205) )/ 2 )
=-3.648/( ( -17.319 + -18.94 )/ 2 )
=-3.648/-18.1295
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source  (OTCPK:CLCS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cell Source ROCE % Related Terms

Thank you for viewing the detailed overview of Cell Source's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell Source Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » ROCE %
Comparable Companies
KAPA SPRB PHGE MEIP HCWB AFMD EDSA IPA SABS LPCN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
57 West 57th Street, Suite 400, New York, NY, USA, 10019
Website
https://www.cell-source.com
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Executives
George Verstraete director 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave director, 10 percent owner 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner 10 percent owner
Yoram Drucker director 31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown director 100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat director, officer: CEO and CFO C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty director C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman director, 10 percent owner C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433